David R. Spigel Announced as Candidate for ASCO Board of Directors

David R. Spigel Announced as Candidate for ASCO Board of Directors

David R. Spigel, MD, FASCO, President and Chief Medical Officer of Sarah Cannon Research Institute (SCRI) and a medical oncologist at SCRI Oncology Partners, has been announced as a candidate for the American Society of Clinical Oncology (ASCO) Board of Directors in the Designated Community Oncologist category.

The position carries a four-year term and represents an opportunity to contribute to the Society’s leadership and decision-making processes, particularly on matters affecting oncology practice and the broader cancer care community.

With experience in clinical oncology, research leadership, and ASCO committee service, Dr. Spigel brings a professional background spanning cancer research, medical practice, and oncology education.

Leading Cancer Research While Remaining Connected to Clinical Practice

Dr. Spigel currently serves as President and Chief Medical Officer at Sarah Cannon Research Institute, alongside his role as a medical oncologist at SCRI Oncology Partners.

His responsibilities reflect two closely connected areas of oncology: the development of clinical research programs and the delivery of cancer care.

As President and Chief Medical Officer, Dr. Spigel holds a senior leadership position within an organization dedicated to advancing cancer research. His continued clinical role at SCRI Oncology Partners also connects his professional activities to the realities of oncology practice.

This combination of research leadership and clinical experience is particularly relevant to the Designated Community Oncologist position on the ASCO Board of Directors, which provides representation for the community oncology perspective within the Society’s governance.

Years of Service to ASCO

Beyond his institutional responsibilities, Dr. Spigel has maintained an active role in ASCO through several volunteer leadership positions.

He previously served as Chair of the Society’s Cancer Communications Committee, contributing to activities focused on the communication of cancer-related information.

He also chaired the ASCO Annual Meeting Education Committee, which plays an important role in shaping the educational content presented during the Society’s Annual Meeting.

These appointments reflect his involvement in two essential areas of professional oncology: communicating developments in cancer care and supporting continuing education for oncology professionals.

Contributing to Clinical Guidelines and Scientific Education

Dr. Spigel’s service to ASCO has also included membership on the Clinical Practice Guidelines Committee and the Annual Meeting Scientific Program Committee.

The Clinical Practice Guidelines Committee supports ASCO’s work in developing evidence-based recommendations to inform oncology practice.

His participation in the Annual Meeting Scientific Program Committee placed him within the Society’s scientific programming activities, which bring research findings and clinical developments to an international audience of oncology professionals.

Together, these roles demonstrate his involvement in the scientific, educational, and clinical practice priorities of ASCO.

Community Oncology at the Board Level

The Designated Community Oncologist seat is an important component of ASCO’s Board of Directors, providing a perspective grounded in the experiences and priorities of oncologists working in community practice.

Community oncology plays a central role in cancer care, particularly in translating research advances and clinical recommendations into treatment decisions for patients.

Dr. Spigel’s candidacy brings together his experience as a practicing medical oncologist, his leadership at Sarah Cannon Research Institute, and his previous contributions to ASCO’s committees.

His professional background connects clinical practice with the research and educational activities that inform modern oncology.

A New Opportunity for ASCO Leadership

Dr. Spigel’s candidacy for the four-year Board of Directors term represents a potential new chapter in his longstanding involvement with ASCO.

Having previously contributed to the Society through leadership roles in cancer communications, education, clinical practice guidelines, and scientific programming, he is now seeking a position within its governing body.

The election will determine the next representative for the Designated Community Oncologist seat, a role that contributes to ASCO’s leadership and its ongoing work on behalf of oncology professionals and patients worldwide.

More articles like this are available on OncoDaily.

Vahe Grigoryan
Fact checked by Vahe Grigoryan MD, Editorial Director
Vahe Grigoryan
Medically reviewed by Vahe Grigoryan MD, Editorial Director